a College of Pharmacy and Nutrition , University of Saskatchewan , Saskatoon , Saskatchewan , Canada.
b Division of Gastroenterology, College of Medicine , University of Saskatchewan , Saskatoon , Saskatchewan , Canada.
J Am Coll Nutr. 2017 Nov-Dec;36(8):646-653. doi: 10.1080/07315724.2017.1342213. Epub 2017 Sep 18.
Evidence from the literature suggests that dietary flaxseed lignans have the ability to modulate inflammation, which is recognized as the underlying basis of multiple chronic human diseases in older adults. Our objective was to determine the effects of oral lignan supplementation on biochemical and functional indicators of inflammation as well as safety and tolerability in older healthy adults. We designed a randomized, double-blind, placebo-controlled clinical trial in older healthy adults (60-80 years) to assess flaxseed lignan-enriched complex (∼38% secoisolariciresinol diglucoside [SDG]; 600 mg SDG dose) oral supplementation effects on biochemical and functional indicators of inflammation and safety and tolerability in older healthy adults after 6 months of once-daily oral administration. The clinical trial confirmed that plasma concentration of total flaxseed lignans (free and conjugated forms) secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (ENL) were significantly associated with daily oral supplementation of flaxseed lignan-enriched complex (p < 0.05). A significant decrease in systolic blood pressure (SBP; from a mean of 155 ± 13 mm Hg at baseline to 140 ± 11 mm Hg at 24 weeks) was observed in lignan-supplemented participants stratified into an SBP ≥140 mm Hg subcategory (p = 0.04). No differences were found between treatment or placebo groups in terms of cognition, pain, activity, physical measurements (calf, waist, and upper arm circumstances), and grip strength. With respect to blood inflammatory markers, lipid profiles, and biochemical parameters, no significant differences were found between treatment and placebo groups at the end of the 6-month supplementation. No adverse effects were reported during supplementation. These data further support the safety and tolerability of long-term flaxseed lignan-enriched complex supplementation in older adults and identify an ability to favorably modulate SBP, an important risk factor in cardiovascular disease.
有文献证据表明,膳食亚麻籽木脂素具有调节炎症的能力,而炎症被认为是老年人多种慢性人类疾病的根本基础。我们的目的是确定口服木脂素补充剂对老年健康成年人炎症的生化和功能指标的影响,以及安全性和耐受性。我们设计了一项随机、双盲、安慰剂对照的临床试验,以评估富含亚麻籽木脂素的复合物(~38%肠二醇葡萄糖苷[SDG];600mg SDG 剂量)口服补充对老年健康成年人炎症的生化和功能指标的影响,以及在每日口服一次 6 个月后的安全性和耐受性。临床试验证实,血浆总亚麻籽木脂素(游离和结合形式)、开环异落叶松树脂酚(SECO)、肠二醇(ED)和肠内酯(ENL)的浓度与口服富含亚麻籽木脂素的复合物的日剂量显著相关(p<0.05)。在木脂素补充组中,收缩压(SBP;从基线时的平均 155±13mmHg 降至 24 周时的 140±11mmHg)显著下降(p=0.04),且 SBP≥140mmHg 亚组的 SBP 下降更为显著。在认知、疼痛、活动、身体测量(小腿、腰围和上臂围)和握力方面,治疗组和安慰剂组之间没有差异。在 6 个月补充结束时,治疗组和安慰剂组之间在血液炎症标志物、血脂谱和生化参数方面没有差异。在补充期间没有报告不良反应。这些数据进一步支持了富含亚麻籽木脂素的复合物在老年人中的长期安全性和耐受性,并确定了其能够有利地调节 SBP 的能力,SBP 是心血管疾病的一个重要危险因素。